SG11201805157TA - Targeted disruption of the mhc cell receptor - Google Patents
Targeted disruption of the mhc cell receptorInfo
- Publication number
- SG11201805157TA SG11201805157TA SG11201805157TA SG11201805157TA SG11201805157TA SG 11201805157T A SG11201805157T A SG 11201805157TA SG 11201805157T A SG11201805157T A SG 11201805157TA SG 11201805157T A SG11201805157T A SG 11201805157TA SG 11201805157T A SG11201805157T A SG 11201805157TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- california
- richmond
- zfns
- Prior art date
Links
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 239000011701 zinc Substances 0.000 abstract 2
- 229910052725 zinc Inorganic materials 0.000 abstract 2
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 abstract 1
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 abstract 1
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 abstract 1
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
WO 17 / 1065 37 A2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106537 A2 22 June 2017 (22.06.2017) WI PO I PCT (51) International Patent Classification: Not classified (21) International Application Number: PCT/US2016/066988 (22) International Filing Date: 15 December 2016 (15.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/269,410 18 December 2015 (18.12.2015) US 62/305,097 8 March 2016 (08.03.2016) US 62/329,439 29 April 2016 (29.04.2016) US (71) Applicant: SANGAMO BIOSCIENCES, INC. [US/US]; 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). (72) Inventors: LEE, Gary K.; c/o Sangamo BioSciences, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). PASCHON, David; c/o Sangamo BioSciences, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). ZHANG, Lei; c/o Sangamo BioSciences, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). (74) Agent: PASTERNAK, Dahna; Pasternak Patent Law, 1900 Embarcadero Rd., Suite 211, Palo Alto, California 94303 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (54) Title: TARGETED DISRUPTION OF THE MHC CELL RECEPTOR Exon 1 og agATGTCT CGC C C GT 3GCCT TA ,CTGT GCTC:GCGC:l'ACTC CTCTTI:.:TU..: :T , :JAGGC ,'ATCCAGC Exon 2 GTAC —, CAAAGAT T ,- :ACI;TTTACTCACGTCATCCAGCAGAGAATGGAAAG TCAAATT TCCTGAATTGC - ':A.AATTTrTC4( - 4 GT T TCAT C CAT CC GACAT T GAAGT T GA GAATGGAGAGA AASTGGAGCAT TCAGACT TGT CT G TTCAGCAA( :ACT TCT T TCTATCTCT TGTACTACACTGAAT T CACCCCCACT 3AAAAAGATGAGTA:3CCTGCCGTG TGAACCATGTEACTTTGT , I., \"ACAGCCCAAGATAGTTAAGTGGE FIG. 1 (57) : Disclosed herein are methods and compositions for inactivating MHC genes, using zinc fmger nucleases (ZFNs) comprising a zinc fmger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Poly- nucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. 1111111111111101110101011111010111110 010110111111101101111111111111111110111111 E
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269410P | 2015-12-18 | 2015-12-18 | |
US201662305097P | 2016-03-08 | 2016-03-08 | |
US201662329439P | 2016-04-29 | 2016-04-29 | |
PCT/US2016/066988 WO2017106537A2 (en) | 2015-12-18 | 2016-12-15 | Targeted disruption of the mhc cell receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805157TA true SG11201805157TA (en) | 2018-07-30 |
Family
ID=59057846
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202005640UA SG10202005640UA (en) | 2015-12-18 | 2016-12-15 | Targeted disruption of the mhc cell receptor |
SG11201805157TA SG11201805157TA (en) | 2015-12-18 | 2016-12-15 | Targeted disruption of the mhc cell receptor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202005640UA SG10202005640UA (en) | 2015-12-18 | 2016-12-15 | Targeted disruption of the mhc cell receptor |
Country Status (14)
Country | Link |
---|---|
US (3) | US10500229B2 (en) |
EP (1) | EP3390437A4 (en) |
JP (3) | JP2018537112A (en) |
KR (1) | KR20180088911A (en) |
CN (2) | CN108699132B (en) |
AU (2) | AU2016374253B2 (en) |
BR (1) | BR112018012235A2 (en) |
CA (1) | CA3008382A1 (en) |
EA (1) | EA201891212A1 (en) |
IL (2) | IL259935B2 (en) |
MX (2) | MX2018007519A (en) |
NZ (1) | NZ743429A (en) |
SG (2) | SG10202005640UA (en) |
WO (1) | WO2017106537A2 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888121B2 (en) * | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and uses thereof |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
IL264565B1 (en) | 2016-08-03 | 2024-03-01 | Harvard College | Adenosine nucleobase editors and uses thereof |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
JP2019530464A (en) | 2016-10-14 | 2019-10-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Nucleobase editor AAV delivery |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
CN110914310A (en) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | Cytosine to guanine base editor |
WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
CN110799492B (en) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids |
CA3062506A1 (en) | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CA3066641A1 (en) * | 2017-06-16 | 2018-12-20 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell and/or hla receptors |
US11512287B2 (en) * | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
US20190048060A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US20200261502A1 (en) * | 2017-09-08 | 2020-08-20 | Carsgen Therapeutics Co., Ltd. | Genetically engineered t cell and application thereof |
CN109517796A (en) * | 2017-09-18 | 2019-03-26 | 博雅辑因(北京)生物科技有限公司 | A kind of gene editing T cell and application thereof |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
AU2018367792A1 (en) * | 2017-11-16 | 2020-06-11 | Mogam Institute For Biomedical Research | Transformed human cell and use thereof |
SG11202003864XA (en) * | 2017-12-13 | 2020-07-29 | Janssen Biotech Inc | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
CN110055223A (en) * | 2018-01-19 | 2019-07-26 | 北京百奥赛图基因生物技术有限公司 | A kind of preparation method and applications of the immunodeficient animals of B2m genetic modification |
US11401512B2 (en) | 2018-02-08 | 2022-08-02 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
EP3752599A1 (en) * | 2018-02-16 | 2020-12-23 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
KR20210008502A (en) | 2018-05-11 | 2021-01-22 | 크리스퍼 테라퓨틱스 아게 | Methods and compositions for treating cancer |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
UY38427A (en) | 2018-10-26 | 2020-05-29 | Novartis Ag | METHODS AND COMPOSITIONS FOR EYE CELL THERAPY |
CA3122762A1 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
CN109722437B (en) * | 2018-12-29 | 2020-01-07 | 广州百暨基因科技有限公司 | Universal CAR-T cell and preparation method and application thereof |
WO2020146805A1 (en) | 2019-01-11 | 2020-07-16 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
CN109706121A (en) * | 2019-01-25 | 2019-05-03 | 苏州茂行生物科技有限公司 | A kind of universal CAR-T cell and its preparation method and application based on base editor |
WO2020191239A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
EP3962938A4 (en) * | 2019-05-01 | 2023-07-05 | PACT Pharma, Inc. | Compositions and methods for the treatment of cancer using a cd8 engineered t cell therapy |
EP4142879A1 (en) | 2020-04-27 | 2023-03-08 | Novartis AG | Methods and compositions for ocular cell therapy |
DE112021002672T5 (en) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE |
IL299491A (en) * | 2020-07-03 | 2023-02-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Methods and compositions for editing the b2m locus in b cells |
WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
EP4259160A1 (en) * | 2020-12-14 | 2023-10-18 | Emendobio Inc. | Biallelic knockout of b2m |
WO2022226020A2 (en) * | 2021-04-20 | 2022-10-27 | Walking Fish Therapeutics | Engineering b cell-based protein factories to treat serious diseases |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE310812T1 (en) | 1994-01-18 | 2005-12-15 | Scripps Research Inst | DERIVATIVES OF ZINC FINGER PROTEINS AND METHODS |
WO1995025809A1 (en) | 1994-03-23 | 1995-09-28 | Ohio University | Compacted nucleic acids and their delivery to cells |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
JP4118327B2 (en) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Improvements in or related to binding proteins for DNA recognition |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5928638A (en) | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
JP4309051B2 (en) | 1998-03-02 | 2009-08-05 | マサチューセッツ インスティテュート オブ テクノロジー | Polyzinc finger protein with improved linker |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
ATE309536T1 (en) | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | METHODS OF USING RANDOMIZED ZINC FINGER PROTEIN LIBRARIES TO IDENTIFY GENE FUNCTIONS |
ATE483970T1 (en) | 2000-02-08 | 2010-10-15 | Sangamo Biosciences Inc | CELLS FOR DRUG DISCOVERY |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US7923542B2 (en) | 2000-04-28 | 2011-04-12 | Sangamo Biosciences, Inc. | Libraries of regulatory sequences, methods of making and using same |
GB2365011A (en) | 2000-04-28 | 2002-02-13 | Sangamo Biosciences Inc | Methods for the characterisation of regulatory DNA sequences |
AU5391401A (en) | 2000-04-28 | 2001-11-12 | Sangamo Biosciences Inc | Targeted modification of chromatin structure |
US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
JP2002060786A (en) | 2000-08-23 | 2002-02-26 | Kao Corp | Germicidal stainproofing agent for hard surface |
AU2001294851B2 (en) | 2000-09-28 | 2007-06-14 | Sangamo Biosciences, Inc. | Nuclear reprogramming using IWSI and related chromatin remodeling atpases |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US7271002B2 (en) | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CN100575485C (en) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | Use the directed karyomit(e) mutagenesis of Zinc finger nuclease |
EP1485475B2 (en) | 2002-03-15 | 2017-09-20 | Cellectis | Hybrid and single chain meganucleases and use thereof |
CA2479858A1 (en) | 2002-03-21 | 2003-10-02 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
CA2514417A1 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Custom-made meganuclease and use thereof |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
EP1732614B1 (en) | 2004-04-08 | 2008-12-24 | Sangamo Biosciences Inc. | Compositions for treating neuropathic and neurodegenerative conditions |
CA2562193A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
US20080131962A1 (en) | 2006-05-25 | 2008-06-05 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
WO2006033859A2 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
MX2007013757A (en) | 2005-05-05 | 2008-01-24 | Univ Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences. |
CA2615532C (en) | 2005-07-26 | 2016-06-28 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
EP2368981A3 (en) | 2005-10-18 | 2011-10-12 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
US9121056B2 (en) * | 2006-04-28 | 2015-09-01 | Igor Kutyavin | Use of products of PCR amplification carrying elements of secondary structure to improve PCR-based nucleic acid detection |
AU2007267874B2 (en) | 2006-05-25 | 2012-03-15 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
ZA200903238B (en) * | 2006-12-14 | 2010-07-28 | Dow Agrosciences Llc | Optimized non-canonical zinc finger proteins |
WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
ATE489465T1 (en) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | TARGETED INTEGRATION INTO THE PPP1R12C POSITION |
AU2008265683B2 (en) | 2007-06-19 | 2013-08-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
NZ584848A (en) | 2007-09-28 | 2012-09-28 | Intrexon Corp | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
EP2281050B1 (en) | 2008-04-14 | 2014-04-02 | Sangamo BioSciences, Inc. | Linear donor constructs for targeted integration |
CA2726768C (en) | 2008-06-10 | 2016-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
JP5908725B2 (en) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for targeted single-strand cleavage and targeted integration |
EP2352369B1 (en) | 2008-12-04 | 2017-04-26 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
DK2459231T3 (en) | 2009-07-31 | 2016-09-05 | Ethris Gmbh | RNA with a combination of unmodified and modified nucleotides for protein expression |
EP2287336A1 (en) * | 2009-07-31 | 2011-02-23 | Exhonit Therapeutics SA | Methods and processes for diagnosing Alzheimer's disease |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
PL2816112T3 (en) | 2009-12-10 | 2019-03-29 | Regents Of The University Of Minnesota | Tal effector-mediated DNA modification |
DK2529020T3 (en) | 2010-01-28 | 2018-08-06 | Childrens Hospital Philadelphia | SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY |
PT2534173T (en) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Engineered cleavage half-domains |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
EP3636766A1 (en) | 2010-05-03 | 2020-04-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
US8945868B2 (en) | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
US9394545B2 (en) | 2011-09-21 | 2016-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
CA3099582A1 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
CA2854819C (en) | 2011-11-16 | 2022-07-19 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
RS60838B1 (en) * | 2012-08-29 | 2020-10-30 | Sangamo Therapeutics Inc | Methods and compositions for treatment of a genetic condition |
DK2906684T3 (en) | 2012-10-10 | 2020-09-28 | Sangamo Therapeutics Inc | T-CELL MODIFIING COMPOUNDS AND USES THEREOF |
EP2929017A4 (en) | 2012-12-05 | 2016-09-28 | Sangamo Biosciences Inc | Methods and compositions for regulation of metabolic disorders |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP2975942B1 (en) | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
EP2997146A4 (en) | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
US9231740B2 (en) | 2013-07-12 | 2016-01-05 | Intel Corporation | Transmitter noise in system budget |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
UA120502C2 (en) * | 2013-11-04 | 2019-12-26 | Дау Агросайєнсиз Елелсі | Optimal maize loci |
ES2895069T3 (en) | 2013-11-13 | 2022-02-17 | Childrens Medical Center | Nuclease-mediated regulation of gene expression |
CA2931848A1 (en) | 2013-12-09 | 2015-06-18 | Sangamo Biosciences, Inc. | Methods and compositions for genome engineering |
BR112016019071A8 (en) * | 2014-03-11 | 2021-07-06 | Cellectis | method for preparing an engineered t-cell, engineered t-cell, and their uses |
EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
-
2016
- 2016-12-15 AU AU2016374253A patent/AU2016374253B2/en active Active
- 2016-12-15 NZ NZ743429A patent/NZ743429A/en unknown
- 2016-12-15 EA EA201891212A patent/EA201891212A1/en unknown
- 2016-12-15 MX MX2018007519A patent/MX2018007519A/en unknown
- 2016-12-15 CN CN201680082170.6A patent/CN108699132B/en active Active
- 2016-12-15 JP JP2018531258A patent/JP2018537112A/en not_active Withdrawn
- 2016-12-15 IL IL259935A patent/IL259935B2/en unknown
- 2016-12-15 IL IL297018A patent/IL297018A/en unknown
- 2016-12-15 CN CN202310912479.5A patent/CN117137947A/en active Pending
- 2016-12-15 SG SG10202005640UA patent/SG10202005640UA/en unknown
- 2016-12-15 WO PCT/US2016/066988 patent/WO2017106537A2/en active Application Filing
- 2016-12-15 KR KR1020187020453A patent/KR20180088911A/en unknown
- 2016-12-15 CA CA3008382A patent/CA3008382A1/en active Pending
- 2016-12-15 SG SG11201805157TA patent/SG11201805157TA/en unknown
- 2016-12-15 US US15/380,723 patent/US10500229B2/en active Active
- 2016-12-15 BR BR112018012235A patent/BR112018012235A2/en active Search and Examination
- 2016-12-15 EP EP16876705.1A patent/EP3390437A4/en active Pending
-
2018
- 2018-06-18 MX MX2022009512A patent/MX2022009512A/en unknown
-
2019
- 2019-11-12 US US16/680,935 patent/US11285175B2/en active Active
-
2020
- 2020-12-07 JP JP2020202691A patent/JP7262434B2/en active Active
-
2022
- 2022-01-19 AU AU2022200341A patent/AU2022200341B2/en active Active
- 2022-02-23 US US17/678,934 patent/US20220175839A1/en active Pending
- 2022-06-24 JP JP2022101756A patent/JP2022121533A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3390437A4 (en) | 2019-10-16 |
IL259935B (en) | 2022-11-01 |
IL297018A (en) | 2022-12-01 |
EA201891212A1 (en) | 2019-01-31 |
US10500229B2 (en) | 2019-12-10 |
US20220175839A1 (en) | 2022-06-09 |
SG10202005640UA (en) | 2020-07-29 |
US20200069735A1 (en) | 2020-03-05 |
WO2017106537A2 (en) | 2017-06-22 |
KR20180088911A (en) | 2018-08-07 |
CN117137947A (en) | 2023-12-01 |
AU2016374253B2 (en) | 2021-10-21 |
JP2022121533A (en) | 2022-08-19 |
NZ743429A (en) | 2022-02-25 |
AU2022200341B2 (en) | 2024-02-08 |
JP2018537112A (en) | 2018-12-20 |
MX2022009512A (en) | 2022-09-02 |
AU2022200341A1 (en) | 2022-02-17 |
MX2018007519A (en) | 2019-09-04 |
JP2021036919A (en) | 2021-03-11 |
WO2017106537A3 (en) | 2017-07-27 |
JP7262434B2 (en) | 2023-04-21 |
BR112018012235A2 (en) | 2018-12-04 |
IL259935B2 (en) | 2023-03-01 |
CA3008382A1 (en) | 2017-06-22 |
US11285175B2 (en) | 2022-03-29 |
AU2016374253A1 (en) | 2018-06-28 |
EP3390437A2 (en) | 2018-10-24 |
CN108699132B (en) | 2023-08-11 |
US20170173080A1 (en) | 2017-06-22 |
CN108699132A (en) | 2018-10-23 |
IL259935A (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805157TA (en) | Targeted disruption of the mhc cell receptor | |
SG11201901364VA (en) | Engineered target specific nucleases | |
SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201908564RA (en) | Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions | |
SG11201906235YA (en) | Narrowband time-division duplex frame structure for narrowband communications | |
SG11201900269XA (en) | Channel sensing for independent links | |
SG11201908489XA (en) | De novo synthesized combinatorial nucleic acid libraries | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201806609TA (en) | Cancer evolution detection and diagnostic | |
SG11201811095UA (en) | Multi-level storage in ferroelectric memory | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201407200TA (en) | Liquid formulation | |
SG11201900699QA (en) | Drug conjugates with self-stabilizing linkers having improved physiochemical properties | |
SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201906973TA (en) | Multiple transgene recombinant adenovirus | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201907738UA (en) | Ranking system for immunogenic cancer-specific epitopes |